In a phase 0 clinical trial, intratumoral administration of mRNA-transfected c-Met-CAR-T cells was applied on patients with metastatic breast cancer with accessible cutaneous or lymph node metastases; it was reported that mRNA c-Met-CAR T cell injections were well tolerated and caused tumor necrosis which was surrounded by macrophages [65]. This evidence concerns the gene MET and metastatic malignant neoplasm in the lymph nodes.